| 1 |
recombinant tissue plasminogen activator
(2474 times)
|
Vascular Diseases
(586 times)
|
NIHSS (188 times)
AIS (170 times)
mRS (153 times)
|
1984 Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
|
| 2 |
recombinant t-PA
(41 times)
|
Vascular Diseases
(17 times)
|
tPA (36 times)
scu-PA (5 times)
MCAO (3 times)
|
1987 Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
|
| 3 |
intravenous tissue plasminogen activator
(10 times)
|
Cardiology
(2 times)
|
AIS (1 time)
APAS (1 time)
EF (1 time)
|
1987 Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial.
|
| 4 |
recombinant tissue plasminogen
(8 times)
|
Medicine
(3 times)
|
CI (2 times)
CT (2 times)
IA (2 times)
|
1991 Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
|
| 5 |
dose-response effectiveness and pharmacokinetics of tissue-type plasminogen activator
(1 time)
|
Cardiology
(1 time)
|
LAD (1 time)
|
1988 Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
|
| 6 |
formation, tissue plasminogen activator
(1 time)
|
Cardiology
(1 time)
|
i.v (1 time)
r-hirudin (1 time)
|
1994 Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
|
| 7 |
glycoprotein, tissue plasminogen activator
(1 time)
|
Biochemistry
(1 time)
|
HPLC (1 time)
|
2006 Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap--Fourier transform mass spectrometry.
|
| 8 |
infarction to primary angioplasty or prehospital fibrinolysis
(1 time)
|
Cardiology
(1 time)
|
---
|
2005 Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial.
|
| 9 |
randomized controlled trial of alteplase
(1 time)
|
Vascular Diseases
(1 time)
|
i.v (1 time)
TESPI (1 time)
|
2012 TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
|
| 10 |
rate, prevalence of INR assay interference, tissue plasminogen activator
(1 time)
|
Nephrology
(1 time)
|
---
|
2006 Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.
|
| 11 |
re-administration of tissue-type plasminogen activator
(1 time)
|
Hematology
(1 time)
|
INR (1 time)
|
2003 The safety and efficacy of repeated courses of tissue-type plasminogen activator in patients with stuck mitral valves who did not fully respond to the initial thrombolytic course.
|
| 12 |
recanalization after intravenous administration of tissue plasminogen activator
(1 time)
|
Neurology
(1 time)
|
AIS (1 time)
SEM (1 time)
TEM (1 time)
|
2020 A case report of thrombolysis resistance: thrombus ultrastructure in an ischemic stroke patient.
|
| 13 |
received intravenous thrombolytic therapy with tissue-type plasminogen activator
(1 time)
|
Neurology
(1 time)
|
BI (1 time)
DWI (1 time)
mRS (1 time)
|
2013 Clinical outcomes of fast MRI-based trombolysis in wake-up strokes compared to superacute ischemic strokes within 12 hours.
|
| 14 |
received open treatment with tissue plasminogen activator
(1 time)
|
Neurology
(1 time)
|
NIHSS (1 time)
|
2008 [Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete].
|
| 15 |
recombinant alteplase
(1 time)
|
Physiology
(1 time)
|
AIS (1 time)
|
2018 Circadian rhythms may not influence the outcomes of thrombolysis in patients with ischemic stroke: A study from China.
|
| 16 |
recombinant DNA coding for the entire sequence of t-PA
(1 time)
|
Drug Therapy
(1 time)
|
tPA (1 time)
|
1984 Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
|
| 17 |
recombinant DNA product
(1 time)
|
Pharmacy
(1 time)
|
tPA (1 time)
|
1987 Tissue plasminogen activator: a new thrombolytic agent.
|
| 18 |
recombinant DNA-derived biological, human tissue-type plasminogen activator
(1 time)
|
Biochemistry
(1 time)
|
---
|
1989 Safety aspects in the quality control of recombinant products from mammalian cell culture.
|
| 19 |
recombinant human single-chain t-PA
(1 time)
|
Hematology
(1 time)
|
tPA (1 time)
|
1993 Competition between plasminogen and tissue plasminogen activator for cellular binding sites.
|
| 20 |
recombinant human tissue PA
(1 time)
|
Cardiology
(1 time)
|
IC (1 time)
PA (1 time)
tPA (1 time)
|
1993 Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
|
| 21 |
recombinant t-PAs produced by Chinese hamster ovary cells
(1 time)
|
Biochemistry
(1 time)
|
FAB-MS (1 time)
mt-PA (1 time)
|
1991 A novel sialylated N-acetylgalactosamine-containing oligosaccharide is the major complex-type structure present in Bowes melanoma tissue plasminogen activator.
|
| 22 |
recombinant tissue PAs
(1 time)
|
Hematology
(1 time)
|
PAs (1 time)
|
2013 Plasminogen activators and ischemic stroke: conditions for acute delivery.
|
| 23 |
recombinant tissue-type
(1 time)
|
Vascular Diseases
(1 time)
|
GP (1 time)
|
2003 Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.
|
| 24 |
Recombinant wild type t-PA
(1 time)
|
Hematology
(1 time)
|
nPlg (1 time)
tPA (1 time)
|
1990 Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
|
| 25 |
recombination plasminogen activator alteplase
(1 time)
|
|
ACI (1 time)
|
2022 Clinical Effect of Butylphthalide Combined with Rt-PA Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction.
|
| 26 |
Regional fibrinolysis with tissue plasminogen activator
(1 time)
|
Medicine
(1 time)
|
---
|
1990 [Regional fibrinolysis with tissue plasminogen activator (rt-PA) (Actilyse)].
|
| 27 |
reocclusion after thrombolysis with plasminogen activator
(1 time)
|
Hematology
(1 time)
|
ASA (1 time)
rHir (1 time)
UFH (1 time)
|
1991 Reocclusion after thrombolysis: a problem solved by hirudin?
|
| 28 |
report on the effects of tissue plasminogen activator
(1 time)
|
Brain
(1 time)
|
GP (1 time)
|
2002 Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
|
| 29 |
report the successful use of low-dose intraventricular thrombolysis
(1 time)
|
Neurology
(1 time)
|
AVM (1 time)
IVH (1 time)
|
2009 Intraventricular thrombolysis for massive intraventricular hemorrhage due to periventricular arteriovenous malformations: no absolute contraindications as rescue therapy prior to surgical repair or embolization?
|
| 30 |
respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator
(1 time)
|
Medicine
(1 time)
|
---
|
1997 [Pulmonary hemorrhage and acute respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator (rt-PA) in patients with acute myocardial infarction].
|
| 31 |
rhTNK-tPA or alteplase
(1 time)
|
Medicine
(1 time)
|
MACCEs (1 time)
PCI (1 time)
rhTNK-tPA (1 time)
|
2017 Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.
|
| 32 |
risk that occurs after the intravenous application of alteplase
(1 time)
|
Pharmacology
(1 time)
|
OA (1 time)
|
2018 Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
|
| 33 |
role of half-dose tissue-type plasminogen activator
(1 time)
|
Medicine
(1 time)
|
LMWH (1 time)
PE (1 time)
|
2021 Low-dose thrombolysis for submassive pulmonary embolism.
|
| 34 |
rt-PA alone
(1 time)
|
Neurology
(1 time)
|
2-MHz (1 time)
FCL (1 time)
PLG (1 time)
|
2011 Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
|
| 35 |
rt-PA in hFFP
(1 time)
|
Emergency Medicine
(1 time)
|
FCL (1 time)
HFFP (1 time)
SD (1 time)
|
2013 Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".
|
| 36 |
rt-PA nonresponders, in that their FCL
(1 time)
|
Emergency Medicine
(1 time)
|
FCL (1 time)
HFFP (1 time)
SD (1 time)
|
2013 Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".
|
| 37 |
telestroke-guided tissue plasminogen activator
(1 time)
|
Brain
(1 time)
|
CT (1 time)
ICH (1 time)
MRI (1 time)
|
2016 Accuracy of Stroke Diagnosis in Telestroke-Guided Tissue Plasminogen Activator Patients.
|
A Search Service for Abbreviation / Long Form